Adlai Nortye (STU:N2U0) Price-to-Tangible-Book : (As of May. 31, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Price-to-Tangible-Book?

As of today (2024-05-31), Adlai Nortye's share price is €6.80. Adlai Nortye's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was €-8.22. Hence, Adlai Nortye's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Adlai Nortye's Price-to-Tangible-Book or its related term are showing as below:

STU:N2U0' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.25 Med: 4.18 Max: 4.18
Current: 3.25

During the past 3 years, Adlai Nortye's highest Price to Tangible Book Ratio was 4.18. The lowest was 3.25. And the median was 4.18.

STU:N2U0's Price-to-Tangible-Book is ranked worse than
59.89% of 1219 companies
in the Biotechnology industry
Industry Median: 2.77 vs STU:N2U0: 3.25

A closely related ratio is called PB Ratio. As of today, Adlai Nortye's share price is €6.80. Adlai Nortye's Book Value per Sharefor the quarter that ended in Jun. 2023 was €-8.22. Hence, Adlai Nortye's P/B Ratio of today is .

Adlai Nortye Price-to-Tangible-Book Historical Data

The historical data trend for Adlai Nortye's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Price-to-Tangible-Book Chart

Adlai Nortye Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

3.83

Adlai Nortye Quarterly Data
	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial			-	-	-	-	3.83

Competitive Comparison of Adlai Nortye's Price-to-Tangible-Book

For the Biotechnology subindustry, Adlai Nortye's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Price-to-Tangible-Book falls into.

Adlai Nortye Price-to-Tangible-Book Calculation

Adlai Nortye's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	6.80	/	-8.219
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Adlai Nortye Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye (STU:N2U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (STU:N2U0) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ANL:USA N2U0:Germany

Address

685 US Highway 1, North Brunswick, NJ, USA, 08902

Website

https://www.adlainortye.com

Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. The company has robust pipeline of drug candidates it includes buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.

Adlai Nortye (STU:N2U0) Headlines

No Headlines